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Abstract
Background: Inflammatory bowel diseases are associated with a variety of extra-intestinal manifestations. The
most frequent of these is joint involvement, which affects 16–33 % of IBD patients. Our aim was to evaluate the
ultrasound prevalence of sub-clinical joint and entheseal involvement in patients with IBD without musculoskeletal
symptoms, and to correlate the US findings with clinical and laboratory variables.
Methods: We recorded the clinical and laboratory data of 76 patients with IBD, 20 patients with spondyloarthritis
(SpA) and 45 healthy controls at three rheumatology centers. All of the IBD patients and healthy controls were
clinically examined by a rheumatologist in order to confirm the absence of musculoskeletal symptoms, and all
of the subjects underwent grey-scale (GS) and power Doppler (PD) US examinations of the second and third
metacarpophalangeal joints, knees and lower limbs in order to detect joint or entheseal abnormalities.
Results: A total of 1410 entheseal sites and 1410 joints were evaluated by US. Of the 76 patients with IBD, 64
(84.1 %) had at least one GS entheseal abnormality, and 11 (13.9 %) had more than one PD-positive entheseal
site; 32 (42.1 %) showed sub-clinical joint involvement.
There was a significant difference between the IBD patients and healthy controls in terms of global entheseal,
PD-positive entheseal, and joint involvement (p < 0.0001), but no difference between the IBD and SpA patients.
Anti-neutrophil cytoplasmic antibodies predicted entheseal involvement in patients with IBD (OR 6.031; p = 0.015).
Conclusions: The prevalence of sub-clinical joint and entheseal involvement was higher in IBD patients than
healthy controls, but there was no difference between the IBD and SpA patients.
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Background
Nearly four million people worldwide are affected by in-
flammatory bowel diseases (IBD) [1], which are associ-
ated with a variety of extra-intestinal manifestations [2].
The most frequent of these is joint involvement, which
affects 16–33 % of IBD patients, [2–4] whereas 5–10 %
are affected by enthesitis [5].
Musculoskeletal involvement is a major concern in
IBD patients as it increases disability and worsens their
quality of life. However, its prevalence is frequently
underestimated because of the transient manifestation of
some oligoarticular patterns or the use of chronic cor-
ticosteroid treatment [6], because enthesitis is mis-
takenly attributed to overuse, or because the recognition
of joint and tendon involvement may be delayed by the
fact that gastroenterologists may not specifically enquire
about musculoskeletal symptoms in everyday clinical
practice [7]. It is therefore necessary to adopt a multi-
disciplinary approach in order to ensure that it is de-
tected and appropriately treated early enough to avoid
poor outcomes.
Ultrasonography (US) is a valid tool of detecting joint
and tendon involvement early in patients with various
rheumatic conditions. It is more sensitive than a clinical
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examination in revealing synovitis [8–13] and enthesitis
[14–18], and can detect pathological changes even in the
absence of symptoms [19–24].
The aims of this US study were to evaluate the preva-
lence of sub-clinical joint and entheseal involvement in
patients with IBD, and correlate the findings with clin-
ical and laboratory data.
Methods
Patients with a definite diagnosis of IBD made by an
experienced gastroenterologist on the basis of clinical,
histological, endoscopic, radiological and laboratory data,
and without any musculoskeletal symptoms were re-
cruited by the outpatient gastroenterology and rheumatol-
ogy departments of the study centers. There were two
control groups: one consisting of patients with spondy-
loarthritis (SpA) diagnosed on the basis of the Assessment
of SpondyloArthritis international Society (ASAS) criteria
[25–27], and the other of age- and gender-matched
healthy subjects.
All of the subjects underwent a rheumatological exam-
ination by an expert rheumatologist blinded to their
clinical condition in order to assess musculoskeletal
involvement, and all of the patients underwent an US
examination of the second and third metacarpophalan-
geal (MCP) joints, knees and lower limbs. The clinical
and US assessments were made separately one immedi-
ately after the other by two investigators who were un-
aware of the other’s findings.
The exclusion criteria were an age of <18 years, a body
mass index (BMI) of >30, a history of any inflammatory,
microcrystalline, degenerative or infectious musculoskel-
etal disease, lower limb peripheral neuropathy, a history
of severe trauma, knee or ankle surgery, or corticoster-
oid injections in the examined structures. IBD patients
with signs of synovitis or enthesitis at clinical examin-
ation were also excluded.
All subjects gave informed consent to participate in
the study, which was conducted in accordance with the
Declaration of Helsinki and approved by Comitato Etico
dell’Azienda Sanitaria Unica Regionale di Ancona.
Clinical assessment
Disease activity in all of the IBD patients was evalu-
ated by a gastroenterologist using the Crohn’s Disease
Activity Index (CDAI) [28] and a modified version of
the ulcerative colitis (UC) Mayo Index [29] without
the endoscopic assessment. CD remission was defined
as a CDAI score of <150 score and UC remission as
≤3 bowel movements without blood.
Data concerning disease duration, the number of
flares, anti-Saccharomyces cerevisiae (ASCA) and peri-
nuclear anti-neutrophil antibodies (pANCA) profiles,
HLA-B 27 status, the erythrocyte sedimentation rate
(ESR), C-reactive protein (CRP) levels, current medica-
tions and BMI were recorded upon study entry.
The rheumatological evaluation was made by an expe-
rienced rheumatologist using a standard protocol that
included confirmation of the absence of musculoskeletal
symptoms or a history of any musculoskeletal disease, or
any disorder that may have had musculoskeletal effects;
the recording of all drugs received in the 12 weeks
preceding study inclusion; a history of bone fracture and
joint surgery; and a physical examination assessing the
swelling and tenderness of the second and third MCP
joints, knees, ankles, and first metatarsophalangeal
(MTP) joint and entheses.
US assessment
The US examinations were performed by one investiga-
tor in each study centre who was blinded to the subject
status and to whom the subjects were asked not to men-
tion their condition. Before beginning the study, the in-
vestigators had reached a consensus concerning on the
scanning technique and the findings to search for. The
machines used were a MyLab Twice (Esaote S.p.A.,
Genova, Italy), a MyLab 70XVG (Esaote S.p.A., Genova,
Italy.) and a GE LOGIQ P5 (General Electric Company,
Little Chalfont, United Kingdom), all of which were
equipped with a 6–18 MHz broadband linear transducer.
Each anatomical area (the second and third MCP joints,
knees, ankles, and first MTP joints) was bilaterally
scanned first in grey scale (GS) in order to detect any
morphostructural changes, and subsequently with power
Doppler (PD with a pulse repetition frequency of 500–
1000 Hz and a Doppler frequency of 6–9.1 MHz) in
order to detect abnormal blood flow. The examination
also investigated the quadriceps, distal and proximal
patellar, Achilles, and proximal plantar aponeurosis
entheseal insertion.
During the multiplanar exploration of the MCP joints,
the subject sat with his or her hands on the examination
table and fingers extended but relaxed. The knee was
scanned with the subject in supine decubitus with the
knee in a neutral position, and the tibiotalar joint with
the subject in supine decubitus, the knee flexed 45°, and
the foot resting over its plantar aspect with slight plantar
flexion. The MTP joints were scanned with the patient
in supine decubitus, the knee flexed 45°, the foot resting
over its plantar aspect, and the toes extended and re-
laxed [30]. During the examinations of the superior
(quadriceps enthesis) and inferior pole of the patella
(patellar enthesis), and the patellar enthesis at the anter-
ior tibial tuberosity, the subject was supine with ex-
tended lower limbs; the Achilles tendon and proximal
plantar aponeurosis were examined with the patient
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lying prone with feet hanging over the edge of the exam-
ination table at 90° of flexion [30].
All of the US findings indicative of enthesopathy were
based on the OMERACT definition [31]. A PD abnor-
mality was considered positive if at least a single vessel
was present at < 2 mm of cortical bone and not at ten-
don body or bursal level.
The supra-patellar pouch, MCP, knee, ankle and
MTP joints were assessed for synovial fluid and syn-
ovial hypertrophy. Synovial fluid was considered docu-
mented in the presence of anechoic or hypoechoic
joint cavity widening displacable/compressible by
ultrasound probe, and synovial proliferation in the
presence of abnormal hypo- or hyperechoic not
compressible material inside the joint cavity [31]. All
sites were scanned in longitudinal and transversal
views and the alterations considered present if seen in
both views. Both the GS and PD findings were qualita-
tively assessed (i.e. present/absent).
Statistical analysis
The continuous variables are expressed as mean values
± standard deviation (SD) or median values and inter-
quartile range (IQR) as appropriate, and the categorical
variables as percentages. The associations between joint/
PDUS/entheseal abnormalities and clinical variables
were evaluated using the Mann–Whitney test in the case
of continuous variables and the χ2 test in the case of cat-
egorical variables. A binary logistic regression model
containing all of the variable that were significant in the
Table 1 Clinical and laboratory characteristics of IBD patients
Crohn’s disease/Ulcerative colitis 43/33 patients
Age 39.93 ± 14.02 years
BMI 23.36 ± 4.13 kg/m2
Disease duration 7.91 ± 6.18 years
Active/inactive bowel disease 51.3 %/48.7 %
Disease flares 2.53 ± 1.97
ASCA positive 25 % (CD)
pANCA positive 18.4 % (17 % UC + 1.4 % CD)
HLA B 27 positive 2.6 %
CRP 0.69 ± 0.96 mg/dL
ESR 14.52 ± 11.48 mm/h
Medications
- Corticosteroids 19.7 %
- 5 ASA 42.1 %
- Anti-TNFα 32.9 %
- Azathioprine 28.9 %
- Cyclosporine 1.3 %
Table 2 Ultrasound findings by disease status
IBD SpA HC
All joints 21 (48.8 %) 8 (40 %) 4 (8.9 %)*
MCP 3 (5.2 %) 1 (1.31 %) 0 (0 %)*
Knee 12 (15.8 %) 6 (30 %) 2 (4.4 %)*
Ankle 7 (11.3 %) 7 (35 %)** 0 (0 %)*
1st MTP 17 (22.4 %) 8 (40 %) 2 (4.4 %)*
All entheseal sites 63 (82.9 %) 20 (100 %) 13 (28.9 %)*
Quadriceps tendon 31 (40.8 %) 11 (55 %) 2 (4.4 %)*
Patellar tendon 51 (67.1 %) 19 (95 %)** 2 (4.4 %)*
Achilles tendon 33 (43.4 %) 13 (65 %) 5 (11.1 %)*
Plantar fascia 19 (25 %) 12 (60 %)** 2 (4.4 %)*
Entheseal power Doppler 25 (32.9 %) 11 (55 %) 0 (0 %)*
Number of subjects with the alteration and their relative prevalence (%)
IBD inflammatory bowel disease, SpA spondyloarthritis, HC healthy controls
*IBD vs HC p < 0.0001; **IBD vs SpA p < 0.01
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Fig. 1 Upper panels: normal enthesis. A1) quadriceps; A2) distal patellar; A3) Achilles; A4: proximal plantar aponeurosis. Lower panels: pathological
enthesis showing increased thickness (blue arrows), enthesophyte (blue arrowhead), calcifications (open arrow) and abnormal blood flow
(asterisk). B1) quadriceps; B2) distal patellar; B3) Achilles; B4) proximal plantar aponeurosis. t – tendon; c – calcaneus bone; tb –tibial bone
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univariate analysis was used to establish the variables
predicting joint/PDUS/entheseal abnormalities.
The data were analyzed using SPSS software, version
20 (Chicago, Illinois, 2011), and a value of p < 0.05 was
considered statistically significant.
Results
One hundred and forty one subjects were recruited: 76
with IBD (43 with CD, and 33 with UC), 20 patients
with established SpA (12 Ankylosing spondylitis, 8 non-
radiographic axial SpA), and 45 healthy controls. Table 1
shows the characteristics of the IBD patients.
US was used to evaluate a total of 1410 entheseal sites
and 1410 joints. Of the 76 patients with IBD, 84.1 % had
at least one entheseal abnormality (from a total of 60
per patient), 50 % had at least three, 40.8 % more than
five, and 17.1 % had more than 10 abnormalities (GS
and PD); 24 (31.6 %) had at least one PD-detected ab-
normality, and 11 were PD-positive at more than one
entheseal site. The patellar tendon was the most affected
entheseal site (a total of 218 detected abnormalities out
of 1824), followed by the quadriceps tendon. Ultrasound
normal and abnormal findings at the four entheseal sites
are exhibited in Fig. 1. Thirty-two of the 76 IBD patients
showed sub-clinical joint involvement. Excluding the
first MTP (because of the frequency of paraphysiological
abnormalities), the knee was the most affected joint (24
irregularities out of 456), followed by the ankle with
eight.
No significant difference was found in the detection
rates of abnormal findings in each institution.
Table 2 shows the prevalence of joint and entheseal in-
volvement. There was a significant difference between
the IBD patients and healthy controls (p < 0.0001), but
no difference between the IBD and SpA patients, and no
apparent difference between the patients with CD and
UC (Table 3).
There was no association between joint involvement
and the clinical or laboratory data of the IBD patients
but, interestingly, global US entheseal abnormalities
were associated with the presence of pANCA (p = 0.011)
and current treatment with azathioprine (p = 0.014).
pANCA also predicted entheseal involvement in the IBD
patients (OR 6.031; p = 0.015). PD-detected entheseal
abnormalities correlated with the number of IBD flares
Table 3 Ultrasound findings in CD and UC
CD UC
All joints 11 (25.5 %) 10 (30.3 %)
MCP 3 (6.9 %) 0 (0 %)
Knee 4 (9.3 %) 8 (24.2 %)
Ankle 4 (9.3 %) 3 (9.1 %)
1st MTP 11 (25.5 %) 6 (18.2 %)
All entheseal sites 37 (86 %) 26 (78.8 %)
Quadriceps tendon 16 (37.2 %) 15 (45.5 %)
Patellar tendon 31 (72.1 %) 20 (60.6 %)
Achilles tendon 16 (37.2 %) 17 (51.5 %)
Plantar fascia 8 (18.6 %) 11 (33.3 %)
Entheseal power Doppler 15 (34.9 %) 10 (30.3 %)
Number of subjects with the alteration and their relative prevalence (%)
No significative difference was found between groups
CD Chron disease, UC Ulcerative colitis
Table 4 Clinical and laboratory data by PD- and GS-detected entheseal abnormalities
PD-detected entheseal abnormalities GS-detected entheseal abnormalities GS + PD detected entheseal abnormalities
present absent p present absent p present absent p
Agea 52 (23.5-58.3) 38 (29–45) 0.707 40 (28–56) 33.5 (24.5-38.5) 0.155 40 (28–56) 33.5 (24.5-38.5) 0.102
BMIa 22.59 (19.9-24.6) 23.24 (19.9-25.9) 0.608 23.4 (20.9-26.4) 21.9 (19.7-24.4) 0.297 23.24 (20.9-26.4) 21.87 (19.7-24.4) 0.297
Disease durationa 6 (2.3-9.5) 7 (4.5-12) 0.695 7 (4–12) 6.5 (4.5-10) 0.724 7 (4–12) 6.5 (4.5-10) 0.972
Disease flarea 2.50 (2–3.75) 3 (2–5) 0.009* 4 (2–5) 2 (1.75-53) 0.204 4 (2–5) 2 (1.75-3) 0.295
Active diseaseb 21 79 0.883 0 100 0.53 9.1 91.9 0.721
ESRa 8.5 (5.3-9.8) 10 (6–17.5) 0.224 8 (5–11) 14.5 (10–29) 0.116 8 (5–11) 14.5 (10–29) 0.196
CRPa 0.35 (0.19-075) 0.19 (0.09-0.8) 0.044* 0.19 (0.1-0.61) 0.4 (0.1-1.3) 0.116 0.19 (0.1-0.6) 0.4 (0.1-1.35) 0.796
ASCAb 15.8 84.2 0.127 78.9 21.1 0.991 30 70 0.822
pANCAb 21.4 78.6 0.476 57.1 42.9 0.022* 16 84 0.011*
Steroidsb 14.3 85.7 0.271 14.2 85.8 0.835 9.4 90.6 0.909
Anti-TNFαb 40 60 0.356 92 8 0.14 37.5 62.5 0.05
AZAb 9 91 0.005* 68.1 31.9 0.030* 23.4 76.6 0.014*
5 ASAb 40 60 0.745 41.2 58.8 0.745 39.1 60.0 0.727
amedian values (interquartile ranges), Mann–Whitney U test; bpercentages (%), χ2 test
PD power Doppler, GS grey scale, CRP C-reactive protein, ESR erythrocyte sedimentation rate, pANCA anti-neutrophil cytoplasmic antibodies, ASCA anti-Saccharomyces
cerevisiae antibodies, AZA azathioprine, 5 ASA 5 asa compounds; *p < 0.05
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(p = 0.009), CRP (p = 0.044) and current treatment with
azathioprine (p = 0.005).
No other associations were found between the clin-
ical and laboratory data and US-detected entheseal in-
volvement (Tables 4, 5 and 6).
Discussion
This is the first multicenter study to explore joint and
entheseal involvement in IBD patients with no signs or
symptoms of musculoskeletal disease and, to the best of
our knowledge, the first time that this has been com-
pared in IBD and SpA patients.
Our findings indicate that the prevalence of sub-
clinical entheseal and joint involvement is in high with
patients with IBD. The prevalence of sub-clinical enthe-
seal involvement is in line with the 92.6 % reported by
Bandinelli et al. [23], although they found a higher
prevalence of PD-detected involvement (32.9 % vs 16 %).
Enthesitis is often the first sign of SpA in young adults
[32], but only a small percentage of cases are discovered
by means of a clinical examination: for example, in a
cross sectional study of 130 Brazilian IBD patients, a
clinical assessment identified enthesitis in only (5,4 %)
[2], and Balint found the sensitivity of a clinical examin-
ation was low in patients with SpA [14].
As found in previous studies [23], the most affected
entheseal site in our patients was the patellar tendon,
followed by the Achilles tendon, which is often indicated
as being the most affected in patients with SpA [33, 34].
On the contrary, the prevalence of frequently described
plantar fascia abnormalities was lowest, possibly because
the thicker layer of subcutaneous tissue and skin in this
anatomical region reduces the sensitivity of US.
Arthritis is a common finding, and has been re-
ported in 17–39 % of patients with IBD [6]. We
found that the prevalence of joint alterations was as
high as 48.8 %, although one magnetic resonance im-
aging (MRI) study of 11 IBD patients with painful
hand joints without clinical synovitis and 11 without
painful joints found no signs of synovitis in the latter
[35]. However, the number of patients was small and
the study only considered hand joints.
Some studies have confirmed the relationship between
sub-clinical gut and joint inflammation [32, 36–38]. The
GIANT cohort study found microscopic gut inflamma-
tion in 46 % of the SpA patients (the prevalence was
higher in those with axial SpA than those with periph-
eral SpA), and one recent MRI study [39] found that
chronic gut inflammation was associated with sacroiliac
joint bone marrow edema.
In our study we found that azathioprine was associated
with increased entheseal involvement in IBD patients. It
has been shown a direct relationship between the extent
of colonic disease and the presence of extraintestinal
manifestations [4]. Patients under treatment with azathi-
oprine could have higher bowel disease activity and
could also have more extraintestinal features including
entheseal involvement. It is also known that azathioprine
is not an effective pharmacological treatment in SpA
and therefore these patients may have more entheseal
manifestations.
We also found an association between pANCA and
entheseal involvement in IBD patients. It has been sug-
gested that atypical pANCA cross-react with luminal bac-
teria and the environmental antigens driving the
inflammatory process [40], and they have also been found
to be associated with isolated colonic disease [41, 42] and
Table 5 Univariate analysis: odds ratios
PD-detected entheseal involvement PD + GS-detected entheseal involvement GS-detected entheseal involvement
Odds
Ratio
95 % CI Odds Ratio 95 % CI Odds
Ratio
95 % CI
Lower Upper Lower Upper Lower Upper
Azathioprine 0.268 0.078 0.921 0.135 0.029 0.635 0.219 0.060 0.790
pANCA 0.228 0.06 0.859 - 0.190 0.049 0.743
GS grey scale, PD power Doppler, pANCA: anti-neutrophil cytoplasmic antibodies, CI confidence interval
Table 6 Multivariate logistic regression models predicting GS- and PD-detected entheseal abnormalities
GS-detected entheseal abnormalities PD-detected entheseal abnormalities GS + PD-detected entheseal abnormalities
Exp (B) 95 % IC p Exp (B) 95 % CI p Exp (B) 95 % CI p
Lower Upper Lower Upper Lower Upper
Azathioprine 2.915 0.775 10.971 0.114 4.210 0.797 22.252 0.091 3.831 0.934 15.716 0.062
pANCA 4.755 1.195 18.915 0.027 - 6.031 1.412 25.757 0.015
Disease flares - 0.704 0.486 1.019 0.063 -
CRP - 1.128 0.641 1.985 0.677 -
GS grey scale, PD power Doppler, pANCA anti-neutrophil cytoplasmic antibodies, CI confidence interval, CRP C-reactive protein
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4-fold risk of undergoing azathioprine treatment [41].
Remarkably, colectomy seems to protect IBD patients
against the development of peripheral arthritis [43].
Interestingly, we did not find any difference in US-
revealed entheseal involvement between our patients
with IBD and those with SpA. A multidisciplinary ap-
proach is useful when following up IBD patients because
the transient nature of the oligoarticular pattern of arth-
ritis, the use of corticosteroids to manage IBD flares [6]
or the attribution enthesitis to overuse, may lead
clinicians to underestimate the prevalence of arthritic
involvement. Moreover, gastroenterologists may not spe-
cifically ask about musculoskeletal symptoms in clinical
daily practice, thus leading to the delayed recognition of
joint and entheseal involvement [7].
This study has some limitations. First of all, as US is
sensitive to small alterations, the fact that the data were
recorded dichotomously may have led to an overestimate
of particularly joint involvement. Secondly, the preva-
lence of pANCA was lower in our patients than that re-
ported in the literature [40–42], and this may have
affected our findings concerning their predictive value
for entheseal involvement. Thirdly, the small study co-
hort did not allow us to measure the real dimension of
the prevalence of entheseal involvement in IBD patients.
Fourthly, the study is not powered enough to detect dif-
ferences between IBD and SpA groups. We estimate a
sample size of 49 for entheseal involvement and 500 for
articular involvement considering a type I error of 0.05
and power of 80 %.
Conclusion
We found a high prevalence of sub-clinical joint in-
flammation in IBD patients without any musculoskel-
etal signs or symptoms, and an association between
pANCA and entheseal involvement, but further stud-
ies are necessary to confirm the latter finding. How-
ever, the question as to how such patients should be
treated and followed up remains open as prospective
studies are necessary in order to clarify the prognostic
value of our findings.
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